Physicians' Academy for Cardiovascular Education

ENGAGE: Factor Xa inhibitor edoxaban with promising results

3' education - Nov. 26, 2013 - AHA 2013 - Bob Giugliano

Dr. Bob Giugliano, senior investigator at TIMI group and associate professor at Harvard, discusses the results and implications of the recently at the AHA 2013 presented ENGAGE trial which evaluated edoxaban, the most recent Factor Xa inhibitor.

News • 3-12-2013

Oral anticoagulant edoxaban is non-inferior and a safe alternative to warfarin

ENGAGE AF-TIMI 48: in this international, large-scale trial two doses of edoxaban gave a reduction of the risk of major bleedings and CV mortality, as compared to well-controlled warfarin.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: